Making Health Care Affordable for the American People Means Holding Big Pharma
Accountable to Lower Drug Prices





 



DOSE OF REALITY: BIG PHARMA’S EGREGIOUS PRICING AND ANTI-COMPETITIVE PRACTICES
ARE DRIVING RISING HEALTH CARE COSTS

Making Health Care Affordable for the American People Means Holding Big Pharma
Accountable to Lower Drug Prices



Big Pharma’s egregious pricing practices and anti-competitive tactics are the
root cause of high prescription drug prices in the United States and a major
driver of rising health care costs for millions of hardworking Americans.



Brand name drug companies set ever higher prices on the products they market,
repeatedly hike prices at rates outpacing inflation and block competition from
more affordable alternatives to keep prices high. Then they spend millions of
dollars pointing fingers at others to evade accountability and rehash debunked
innovation rhetoric to undermine market-based solutions to lower drug prices
for American patients and taxpayers.



Making health care more affordable for the American people means holding Big
Pharma accountable to lower prescription drug prices. Get a Dose of Reality on
how Big Pharma is responsible for high prescription drug prices and health care
inflation in the United States here:



BIG PHARMA’S EGREGIOUS PRICING PRACTICES



Price Hikes Outpacing Inflation

* Big Pharma Kicked Off 2026 With 872 Price Hikes On Brand Name Drugs: Brand
name pharmaceutical companies increased prices on872
<[link removed]>
prescription drugs to start the year, with a median increaseoutpacing
<[link removed]>
the rate of inflation.
* Drug Prices Have Outpaced Inflation For Nearly Two Decades: A January 2024
report
<[link removed]>
from AARP’s Public Policy Institute found that manufacturers raised prices
faster than inflation on 943 top-selling brand name drugs in all but one year
between 2006 and 2020.
* Brand Name Drug Companies Nearly Double Prices On Medications Most Often
Needed By America’s Seniors Since They First Entered Market:A 2025 report
<[link removed]>
from AARP’s Public Policy Institute found that the list prices of Medicare
Part D’s top 25 best-selling prescription drugs increased by an average of 98
percent – or nearly double – since entering the market. The report found that
“20 of the top 25 drugs’ lifetime price increases greatly exceeded the
corresponding rate of general inflation.”
Out-of-Control Launch Prices on New Drugs

* Median List Price of Newly Launched Drugs Exceeded $370,000 In 2024: A May
2025 Reutersanalysis
<[link removed]>
found that the median list price of newly launched prescription drugs in the
United States topped $370,000 in 2024, more than double the median price in
2021.
* Launch Prices For New Drugs Rose 24 Percent Between 2022 And 2024: An
October 2025analysis
<[link removed]>
from the Institute for Clinical and Economic Review (ICER) found that the
inflation-adjusted median annual list price for newly launched drugs increased
24 percent between 2022 and 2024.
* Median Launch Prices Tripled from 2011 to 2022: A March 2023 report
<[link removed]>
from The Wall Street Journal found that the median monthly price for a newly
approved drug nearly tripled from 2011 to 2022
BIG PHARMA’S ANTI-COMPETITIVE TACTICS THAT KEEP PRICES HIGH

* Patent Abuse On Just Four Blockbuster Drugs Cost $3.5 Billion in Two Years:
In August 2025, astudy
<[link removed]>
published in JAMA Health Forum found that lost competition due to Big Pharma’s
patent thickets on just four widely prescribed brand name drugs cost patients,
taxpayers and the U.S. health care system more than $3.5 billion in excess
spending over two years.
* Big Pharma’s Patent Thickets On Just Five Drugs Cost Over $16 Billion In a
Single Year: A January 2023 report
<[link removed]>
from Matrix Global Advisors, “Patent Thickets and Lost Drug Savings,”
quantified the one-year cost of lost savings on five brand name drugs around
which Big Pharma has built especially egregious patent thickets. The five drugs
were AbbVie’s autoimmune drug Humira and oncology drug Imbruvica, Regeneron’s
ophthalmology drug Eylea, Amgen’s autoimmune drug Enbrel and Bristol Myers
Squibb’s oncology drug Opdivo.
* Targeting Blockbuster Products for Patent Abuse: A May 2022 study
<[link removed]>
published in the Journal of the American Medical Association (JAMA) Health
Forum revealed how brand name drug companies target their most profitable
products for reformulation to extend monopolies and prohibit generic
competition from entering the market.
* Big Pharma Increasingly Utilizing Secondary Patents to Extend Monopoly
Pricing:A January 2026 study
<[link removed]>
published in JAMA Health Forum highlights how Big Pharma has been increasingly
relying on secondary and tertiary patents that are unconnected to the active
pharmaceutical ingredients (API) in top-selling drugs to extend monopoly
pricing. Among 331 analyzed drugs, manufacturers “listed 3,241 patents in the
FDA’s Orange Book…more than half – 54 percent – were tertiary patents covering
devices or device-related features, while only 4.2 percent were primary patents
on the active pharmaceutical ingredient.”
* Delayed Generic And Biosimilar Competition Costs U.S. Health System
Hundreds Of Billions In Excess Spending: An analysis
<[link removed]>
from the Association for Accessible Medicines estimated that accelerating
access to generic and biosimilar drugs could generate $422.9 billion in savings
by reducing prices through competition.
BIG PHARMA’S PRICES ARE DRIVING HEALTH CARE INFLATION

* CSRxP Analysis Finds Big Pharma Profit Margins 10 Times Higher Than Others
in Supply Chain: Recently released findings from a CSRxP analysis reveal that
the pharmaceutical industry continues to post profit margins 10 times higher
than other sectors of the prescription drug supply chain.
* High Launch Prices and GLP-1 Prices Driving Inflation: A July 2025 analysis
<[link removed]>
from PwC identified new prescription drugs entering the market as one of the
main inflationary drivers for medical costs heading into 2026, pointing in
particular to the high cost of new GLP-1 drugs, cell and gene therapies and
treatments for rare diseases.
* Prescription Drug Spending Grew 11.4 Percent In 2024: A 2024 IQVIA analysis
<[link removed]>
of national drug spending found total prescription drug expenditures increased
11.4 percent in 2024, driven largely by high-priced brand name drugs, including
GLP-1 medications, oncology therapies and immunology treatments.
* Prescription Drug Price Inflation Rising Even as Other Health Care Prices
Fall: An August 2024 Peterson-KFF Health System Tracker analysis
<[link removed](CPI-U)%20for%20medical%20care,%20by%20category,%20June%202023%20-%20June%202024>
found the annual Consumer Price Index (CPI) for prescription drugs rose 2.4
percent from June 2023 to June 2024, while the CPI for health insurance
decreased 4.2 percent over the same period.
* Brand Name Specialty Drugs And Biologics Account For More Than Half of All
Drug Spending Despite Being Just Five Percent Of Prescriptions: According to
federal health spending data
<[link removed]>
, brand name specialty drugs and biologics represent more than 51 percent of
total prescription drug spending, even though they account for only five
percent of prescriptions filled in the United States.
* Retail Prescription Drug Spending Reached $467 Billion In 2024: According
to a January 2026research article
<[link removed]> in Health
Affairs, national retail prescription drug spending totaled $467 billion in
2024, up 7.9 percent. The number of new active substances in medications
launched by drug companies decreased from sixty-five in 2023 to forty-eight in
2024—the lowest number of new active substances since 2019.
AMERICANS RIGHTLY RECOGNIZE BIG PHARMA AS RESPONSIBLE FOR HIGH PRICES AND
SUPPORT BIPARTISAN MARKET-BASED SOLUTIONS

* Clear Majority of U.S. Voters View Big Pharma as Responsible for High Drug
Costs: According to a February 2025 Fabrizio Ward survey
<[link removed]>
, 62 percent of voters view drug companies as the most responsible for high
drug costs out of eight options.
* Three in Five Voters Identify Drug Company Profits as Main Driver of High
Prices:59 percent of voters blame drug company profits as the main driver of
high prescription drug prices.
* Nine in 10 Voters Concerned With Price Hikes Disconnected from Innovation:
91 percent of voters are concerned that in 2023, brand name drugmakers
increased prices on five widely used prescription medications without any
accompanying true innovation, costing U.S. patients and the health care system
an additional $815 million.
* Nine in 10 Voters Concerned with Big Pharma’s Price Gouging and
Anti-Competitive Tactics: 89 percent of voters are concerned Big Pharma has a
long history of price-gouging patients through tactics designed to game the
U.S. patent system and block competition from more affordable alternatives,
including patent thickets made up of hundreds of patents on blockbuster drugs.
Read more on Big Pharma’s egregious pricing practices from last year HERE
<[link removed]>
.



Read more on the cost of Big Pharma’s unjustified price hikes HERE
<[link removed]>
.



Read more on bipartisan, market-based solutions to hold Big Pharma accountable
HERE <[link removed]>.



About CSRxP: The Campaign for Sustainable Rx Pricing <[link removed]>
is a broad-based coalition of physicians, nurses, hospitals, consumers, health
plans, pharmacy benefit managers, pharmacists and businesses promoting
bipartisan, market-based solutions to lower drug prices. Learn more:
www.csrxp.org <[link removed]>



###

































Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>